Medical weight management — treating weight as a health issue, not a willpower issue

In brief

• Excess weight is a medical condition that drives type 2 diabetes, high blood pressure, fatty liver, sleep apnoea, heart disease and several cancers.
• Singapore uses lower BMI cut-offs: 23 to 27.4 is overweight, and 27.5 or above is obese.
• Losing 5 to 10% of body weight over 6 to 12 months brings most of the metabolic benefit.
• Lifestyle change is the foundation; medication is worth discussing from a BMI of 27.5, or from 23 with a weight-related condition.
• Semaglutide (Wegovy) and tirzepatide (Mounjaro) gave about 15% and 20–22% weight loss in trials, but weight usually returns after stopping.
• Surgery may suit a BMI of 32.5 or above with metabolic conditions, or 37.5 or above alone.

We offer medical weight management at our Punggol clinic, with or without medication. See our weight management programme.

Weight as a medical issue — what it drives

Excess weight affects almost every organ system, especially fat stored in and around the organs (abdomen, liver, pancreas, muscle, heart). It drives or contributes to:

• Type 2 diabetes and prediabetes (weight is the biggest driver locally)
• High blood pressure
• Dyslipidaemia, particularly raised triglycerides and low HDL
• Chronic kidney disease
• Cardiovascular disease: coronary artery disease, heart failure, atrial fibrillation and stroke
• Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease (NAFLD), now Singapore’s most common chronic liver disease
• Obstructive sleep apnoea: increasingly common, often undiagnosed, linked to weight both ways
• Gastro-oesophageal reflux
• Osteoarthritis, particularly of the knees and hips
• At least 13 cancers, including post-menopausal breast, colorectal, endometrial, kidney, oesophageal, pancreatic, liver and gallbladder cancers
• Fertility problems in men and women, polycystic ovary syndrome, gestational diabetes and pregnancy complications
• Depression, anxiety and binge-eating disorder, often both cause and consequence
• Functional limitation (stamina, sleep quality, joint pain) that erodes quality of life

This is why treating weight often does more for overall health than treating any one of these conditions. A 10–15% weight reduction can normalise blood sugar in early type 2 diabetes. It can also lower blood pressure, improve sleep apnoea, resolve fatty liver in many patients and take years off cardiovascular risk.

See also our guides to cardiovascular-kidney-metabolic (CKM) health, diabetes and cholesterol.

How we assess it — beyond the number on the scale

BMI — with Asian-adjusted thresholds

Body mass index (BMI) is weight in kg divided by height in m². Singapore and other Asian populations use lower cut-offs than European data, because metabolic complications appear at lower BMIs.

A BMI of 25 is “just overweight” by Western criteria but already signals meaningful metabolic risk in an Asian patient.

When BMI doesn’t apply. BMI is a useful screening tool for most adults between 18 and 65, but not for:

• Under 18s: growth charts are used instead.
• Pregnancy: weight change is expected and managed separately.
• Very muscular people (e.g. athletes, bodybuilders): a high BMI may reflect muscle rather than fat.
• Older adults (65 and above): we look more at weight trajectory, unintentional loss, muscle strength and frailty than at the number. Unintentional weight loss in an older adult is always worth investigating.

Waist circumference

BMI misses where the weight is. Abdominal (visceral) fat is far more harmful than fat on the hips and thighs, so a lean person with a large waist still carries substantial metabolic risk.

Singapore’s thresholds for increased risk are ≥ 90 cm for men and ≥ 80 cm for women.

Measure on bare skin, midway between the lowest rib and the top of the hip bone, at the end of a normal breath out (no breath-holding).

Body composition

In selected patients we use bioelectrical impedance analysis (BIA) or similar to estimate body fat percentage, visceral fat rating and muscle mass. This helps us:

• Check for excess fat when BMI is borderline, as in very muscular patients or older patients with reduced muscle.
• Track progress. Losing visceral fat while keeping muscle is far better than losing muscle.
• Screen older patients for sarcopenic obesity: adequate fat but low muscle mass, which carries its own risks.

Metabolic workup

At the first weight-focused visit we usually check:

• Fasting glucose and HbA1c
• Lipid panel
• Liver enzymes (ALT, AST, GGT), and sometimes a liver ultrasound if MASLD is suspected
• Thyroid function (TSH), since hypothyroidism is a reversible cause
• Kidney function (eGFR) and UACR
• Blood pressure
• Vitamin D, often low and relevant to muscle and mood
• A sleep study, if obstructive sleep apnoea is likely (significant snoring, witnessed apnoeas, unrefreshing sleep, daytime fatigue)

Metabolic syndrome — a pattern worth checking for

We also look for metabolic syndrome, a cluster of findings that together carry more risk of type 2 diabetes and cardiovascular disease than any one alone. By the Singapore-adjusted definition, you have it with any three of these five traits:

It doesn’t change treatment much, since each condition is treated on its own merits. But it summarises cardiometabolic risk and can prompt earlier action.

The target we aim for

For most patients with a BMI ≥ 23 kg/m² or a high-risk waist, a reasonable first goal is to reduce body weight by 5 to 10% over 6 to 12 months, through lifestyle change and, where appropriate, medication.

This is where most of the metabolic benefit shows up:

• Lower blood pressure
• A better lipid profile
• Much better blood sugar and insulin sensitivity
• Less fatty liver
• Slower progression of obstructive sleep apnoea
• Often enough to put early type 2 diabetes into remission, or to delay progression from prediabetes

Many patients lose more, especially on newer medications, but 5–10% is realistic for most people. The goal is durable loss, not rapid loss.

What’s driving weight gain

Treating weight as a willpower problem has caused real harm. Biology, environment and behaviour all play a part.

Biology carries most of the load

Body weight is tightly regulated. Hormones (leptin, ghrelin, GLP-1, PYY, GIP, insulin, cortisol), the hypothalamus and the gut microbiome control appetite, fullness, metabolic rate, fat storage and energy use. After weight loss, the body defends its stored weight and pushes towards regain for many years: metabolic rate falls, hunger rises and fullness fades.

This is why diets work in the short term and fail in the long term. The body recalibrates its set point; willpower is not the problem. The newer medications (GLP-1 receptor agonists, tirzepatide) work partly by shifting this set point, a different mechanism from “eat less”.

Genes contribute substantially too. Monogenic obesity is rare, but polygenic predisposition is common, and body weight is about as heritable as height.

Environment is the accelerant

Singapore’s food environment, like most of the developed world’s, is engineered for overeating. Ultra-processed foods are designed to be tasty, convenient, calorie-dense and quick to eat. Portions, meal frequency, sugar content and daily temptation have changed meaningfully in 30 years. This is a population-wide shift, not a personal character defect.

Other contributors

• Sleep deprivation and shift work disrupt appetite hormones.
• Chronic stress raises cortisol, which drives visceral fat.
• Certain medications contribute: insulin, some diabetes drugs (especially sulphonylureas, older insulins), several antipsychotics, some antidepressants, long-term oral corticosteroids, some blood-pressure medicines and some contraceptives.
• Hormonal conditions include hypothyroidism, polycystic ovary syndrome, and rarely Cushing’s syndrome or pituitary problems.
• Perimenopause and menopause often bring body composition change independent of food intake.
• Life transitions such as pregnancy, child-rearing, bereavement, job stress or illness often set a new weight trajectory.

The lifestyle foundation — what sustainable change looks like

Medication without lifestyle change works poorly. Lifestyle change without medication often works for a while, then fails. For most patients the answer is both, set up realistically.

Food pattern

We look for a pattern you can keep for years, not a named diet. The best-evidenced is a plant-forward, Mediterranean or DASH-style pattern (Dietary Approaches to Stop Hypertension), adapted locally:

• More vegetables: at least half of most plates
• Smaller portions of rice, noodles and bread; brown rice, quinoa or oats where you enjoy them; fewer sugary drinks
• Protein at every meal: fish, tofu, eggs, lean meat, dairy, beans. More protein helps preserve muscle during weight loss.
• Healthy fats: olive oil, avocado, nuts, fatty fish
• Less ultra-processed food, the biggest practical lever in most diets

What matters less than often claimed:

• Exact macronutrient ratios: very-low-carb, Mediterranean, DASH, plant-based and intermittent fasting give similar long-term results if you stick to them. The best diet is the one you can sustain.
• “Cleanses”, juice diets and extreme restriction: short-term loss, high rebound, usually counterproductive.

Physical activity

• 150–300 minutes per week of moderate-intensity activity, such as brisk walking, cycling or swimming
• Resistance training, 2 sessions per week, particularly to preserve muscle during weight loss
• Less sitting through the day: standing desks, walking meetings, stairs
• Activity you will keep doing beats activity that looks best on paper

Weight loss on medication improves metabolic health even without exercise. But activity also protects muscle, further improves cardiometabolic markers, and supports mood and sleep.

Starting exercise at a higher BMI or with comorbidities. At higher-risk BMIs (≥ 27.5 with comorbidities, or ≥ 32.5), we usually do an exercise pre-participation assessment before recommending structured programmes. We check blood pressure, heart rate response, symptoms on exertion, joints and medicines that affect exercise, so that what you do is safe. Lower-risk patients can usually use a self-check such as the Get Active Questionnaire or PAR-Q.

Sleep

• 7–9 hours per night is a weight-management intervention.
• We screen for obstructive sleep apnoea if you have significant snoring, witnessed apnoeas, daytime sleepiness or resistant hypertension. OSA worsens weight gain and improves with weight loss.

Behaviour and stress

• Mindful eating helps separate physical hunger from stress, boredom or emotional triggers.
• Cognitive behavioural approaches to eating are evidence-based, especially for binge-type patterns.
• Stress management helps, since stress-driven cortisol promotes visceral fat and insulin resistance.
• Your food environment: what’s within easy reach at home and work usually gets eaten.

Alcohol and smoking

• Alcohol adds empty calories, loosens food choices and disrupts sleep. Keep to no more than 2 standard drinks a day for men and 1 for women (less is better), or take a break while losing weight.
• Smoking: weight is a good reason not to start. But quitting is rarely the right time to add aggressive weight loss, so we time the two carefully.

When medication is appropriate

No rule says everyone above a BMI threshold needs medication, or that it is only for the severely affected. The question is whether benefit outweighs risk and cost for you.

Medication is usually worth discussing when:

• BMI is ≥ 27.5 (the Asian cut-off for obesity)
• BMI is 23–27.4 plus a weight-related condition: type 2 diabetes, prediabetes, hypertension, dyslipidaemia, MASLD, CKD, obstructive sleep apnoea or significant osteoarthritis
• Lifestyle change has had a fair trial, usually 3–6 months of structured effort, without reaching target
• The biology is clearly unfavourable (strong family history, past weight trajectory, metabolic findings) and waiting is probably not the best approach

It is less appropriate when:

• BMI and metabolic results are in the low-risk range
• Medicalising weight could harm your relationship with food and body image (for example, after a restrictive eating disorder)
• You are pregnant or planning pregnancy
• The cost is unaffordable and would displace more important treatment

We don’t prescribe weight medication without a proper conversation first. It is a clinical decision, not a transaction.

The medications we use

Incretin-based therapies (GLP-1 receptor agonists and tirzepatide) have transformed the field in the last five years, because their effect is much larger than anything before.

GLP-1 receptor agonists

These mimic glucagon-like peptide-1, a gut hormone released after eating. They slow stomach emptying, increase fullness, reduce appetite and reset the brain’s set point for body weight. For weight management in Singapore we use:

• Semaglutide (Wegovy): weekly injection under the skin, increased gradually over several months. Trial weight loss at the optimal dose was around 15% of body weight over 68 weeks.
• Liraglutide (Saxenda): daily injection under the skin. Typical weight loss is around 8–10%.

These are the same molecules as Ozempic and Victoza, which are registered for diabetes; the dosing and indication differ.

What they do well:

• Substantial weight loss, sustained while you continue
• Cardiovascular benefit in high-risk patients (particularly semaglutide)
• Better glucose, lipids, blood pressure, fatty liver and sleep apnoea
• Well tolerated by most patients once the dose is built up

Common side effects:

• Nausea, usually worst in the first few weeks of a new dose, then easing. Slow dose increases help.
• Constipation, heartburn, feeling full early
• Occasional vomiting, usually with large or fatty meals
• Rare but important: pancreatitis (stop if you have severe abdominal pain), gallstones (particularly with rapid weight loss) and, rarely, gastroparesis

Points worth knowing:

• Titration: the dose starts low and rises gradually to reduce nausea.
• Sick days: if you are acutely unwell, vomiting or unable to eat normally, hold the next dose and contact us.
• Injection technique is simple; we teach it in clinic, and our diabetes injectables guide has details.

Tirzepatide — Mounjaro

Tirzepatide activates two gut hormone receptors, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). It is a weekly injection under the skin. Trial weight loss at the highest dose was around 20–22% of body weight in the SURMOUNT-1 trial, among the largest effects seen with the medicines currently approved for weight management.

• Mounjaro: registered in Singapore for type 2 diabetes and, since June 2025, for weight management. Supply can vary, so we confirm availability at your visit.
• Zepbound: the brand name for the same drug in the United States.

Side effects are similar to GLP-1 receptor agonists: mainly gastrointestinal, especially during dose increases.

Orlistat (Xenical)

An older medicine that works locally in the gut by blocking pancreatic lipase, so less dietary fat is absorbed. Typical weight loss is around 3–5% of body weight: modest next to the incretins, but clinically meaningful for some.

Side effects depend directly on fat intake: oily stools, wind, urgency, and occasionally fat-soluble vitamin deficiency with long use. Eating less fat means more weight loss and fewer side effects.

Orlistat costs less than the injections. It suits people who want an oral medicine, can’t afford or don’t want injections, or don’t tolerate GLP-1-based options.

What we generally don’t recommend

• “Compounded GLP-1 peptides”: unregulated preparations, often sold online or through non-medical channels, with variable and sometimes poor-quality active ingredient.
• Unregulated weight-loss supplements (mega-dose green tea extract, garcinia cambogia, “fat burner” stacks, unlabelled herbal products): evidence ranges from weak to harmful, and some have been linked to severe liver injury.
• Unsupervised very-low-calorie diet (VLCD) programmes: 800 kcal/day programmes can work, but they are medical interventions and should be supervised. “Meal replacements” from non-medical sources often aren’t.
• Sibutramine (Reductil) and fenfluramine-phentermine combinations: withdrawn globally and in Singapore. Anything offered under these names is not legitimate.

If you take any weight-loss product we haven’t prescribed (over-the-counter, herbal or supplement), bring the packaging to your next visit.

Bariatric and metabolic surgery — when it’s the better option

Surgery is worth considering for significant obesity: particularly a BMI ≥ 32.5 with metabolic comorbidities, or ≥ 37.5 alone (Singapore’s Asian-adjusted thresholds). It often gives more durable weight loss and more complete remission of obesity-related conditions than medication alone.

Common procedures:

• Laparoscopic sleeve gastrectomy: the most commonly performed in Singapore; 70–80% of the stomach is removed.
• Roux-en-Y gastric bypass: food is rerouted past part of the stomach and upper small intestine.
• Gastric band: out of favour because of higher complication and revision rates; not generally used now.

Typical weight loss is around 25–30% of body weight at 1–2 years, with good long-term durability and significant rates of type 2 diabetes remission. The trade-offs are surgical risk, lifelong follow-up and supplements (vitamin B12, iron, calcium, vitamin D), a permanent change in how you eat, and the need for strong psychological support.

Surgery is specialist-led, and we refer to local bariatric teams. If you might qualify, we can discuss eligibility, realistic outcomes and the assessment process.

The newer medications have changed when surgery is the best option. Some patients who once would have gone straight to surgery now do as well on tirzepatide alone, at least in the medium term. For others, surgery remains the better choice. We decide this with you, not for you.

Common questions

“Is taking medication for weight a form of cheating?”

No. You are treating a medical condition that responds to treatment, just as you would treat high blood pressure.

If medication improves your health, quality of life and long-term outlook, it is appropriate treatment. Your feelings about it are worth discussing, but they are not a medical reason to avoid it.

“Will I regain weight if I stop?”

For most patients, yes, at least partly. Studies of semaglutide, tirzepatide and related medicines consistently show substantial regain over 12–18 months after stopping, as the biology reverts.

Obesity is a chronic condition, and this is chronic treatment. It is like blood-pressure medication: stop it, and blood pressure usually goes back up. The real question is whether the benefit-to-cost balance justifies continuing.

Still, not everything gained is lost. Metabolic improvements often outlast the weight loss, and habits built during treatment can persist. Some patients maintain their weight after stopping; many don’t.

“Is it safe long-term?”

The incretin-based medicines have a safety record of roughly 15–20 years. Liraglutide was first approved in 2010, semaglutide in 2017 and tirzepatide in 2022. Pharmacovigilance programmes worldwide continue to monitor for rare effects.

What we know:

• Cardiovascular safety is reassuring, and semaglutide has shown cardiovascular benefit in high-risk patients.
• Kidney safety is favourable. In people with type 2 diabetes and chronic kidney disease, semaglutide (at its diabetes dose) lowered the risk of major kidney disease events by 24% in the FLOW trial (2024).
• Pancreatitis is uncommon but possible. Severe abdominal pain means stop and call us.
• Gallstones are more common with rapid weight loss (not specific to these medicines).
• A thyroid C-cell tumour signal in rodent studies has not translated to humans at clinically meaningful rates. But a personal or family history of medullary thyroid cancer or MEN2 is a reason to avoid these medicines.
• Questions remain about very long-term muscle preservation, particularly in older patients.

The side effects that most often make patients stop are gastrointestinal and dose-limiting, not serious.

“How much does it cost?”

Costs vary. The newer medicines (Wegovy, Mounjaro) are currently expensive in Singapore; Saxenda usually costs less but is still significant. MediSave coverage is limited and CHAS does not usually cover them for weight, though the same molecules are sometimes partly covered for diabetes. We discuss cost at the first conversation, including cheaper options (orlistat, lifestyle only, or surgery) where appropriate. Programme details are on our medical weight management page.

“Will I feel terrible on it?”

Most patients have some stomach symptoms in the first 1–2 weeks after each dose increase. Slow dose increases, smaller meals, avoiding fatty or fried food, and stopping before you feel “full” all help. If side effects persist or are severe, we adjust.

“Can I lose weight without medication?”

Yes, some people can, and lifestyle change alone should be tried first where reasonable. Some do very well on it; others have already tried hard and deserve more effective tools. The question is which path is most effective and sustainable for you now.

Long-term care and maintenance

Keeping weight off is harder than losing it, because the biology of regain is powerful. A long-term plan usually includes:

• A maintenance dose, often lower than the weight-loss dose
• Check-ins quarterly in the first year, then every 6–12 months if stable
• Monitoring of weight, waist, blood pressure, glucose, lipids, kidney function and liver enzymes
• Resistance training to preserve muscle, which matters more as weight comes off
• A plan for life events such as illness, surgery, travel, pregnancy and ageing
• Frank conversations when the plan isn’t working, rather than drifting

Small regain is common and rarely a disaster. Large regain over a short time signals that something has changed; talk to us rather than blaming yourself.

The Singapore context — what’s available to you

Healthier SG and the weight-management pathway

Weight management sits within Healthier SG, the national preventive-care framework. If you are enrolled with us, weight review is part of your chronic-care plan.

Support runs from self-directed to specialist-led:

• Self-directed activity and preventive programmes: the Healthy 365 (H365) app tracks steps, active minutes and diet, and links to programmes from HPB, SportSG and People’s Association. It suits self-motivated people at low-to-moderate risk.
• Structured community weight-management programmes: group sessions, lifestyle counselling and exercise guidance for moderate-to-high BMI or chronic conditions. SportSG’s Active Health Manage Series (Metabolic and Musculoskeletal-Knee categories as of 2026) is the current structured pathway for our weight-focused patients.
• Primary Care Network (PCN) care teams: allied health counselling (nutrition, activity coaching) we can add for more individual support.
• Tertiary weight-management programmes: hospital multidisciplinary obesity clinics for the most intensive care, usually for a BMI ≥ 32.5 with significant comorbidities, or ≥ 37.5 alone. We make the referral.

We match you to the part of the pathway that fits, and adjust as things change.

Cost and subsidy

• MediSave coverage for weight-management medicines is limited; most weight indications can’t be claimed. Some molecules are partly claimable for diabetes.
• CHAS focuses on chronic disease medicines, not weight prescriptions.
• HSA strictly regulates unapproved weight-loss products. Products sold outside regulated pharmacies or clinics are usually unregulated, so bring them to us before taking them.
• Bariatric surgery is available in public restructured hospitals and private centres. MediSave and insurance coverage vary widely; we help you plan the costs as part of the referral.

Get in touch

Punggol — 658 Punggol East, #01-04, Singapore 820658 · Tel 6312 4589

Joo Chiat — 172 Joo Chiat Road, #01-01, Singapore 427443 · Tel 6920 1952

Email — admin@ktmc.sg

References

Guidelines and consensus statements

• Ministry of Health, Singapore / Health Promotion Board. HPB–MOH Clinical Practice Guidelines 1/2016: Obesity.
• Ministry of Health, Singapore. Healthier SG Care Protocol — Body Mass Index (BMI) Control. Updated April 2026. primarycarepages.sg
• American Association of Clinical Endocrinology (AACE) / American College of Endocrinology. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. aace.com
• The Obesity Society / American Heart Association / American College of Cardiology. AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.
• Obesity Medicine Association. Obesity Algorithm 2024–2025. obesitymedicine.org
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
• Health Promotion Board Singapore. Metabolic Syndrome — patient and clinician resources. healthhub.sg
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the IDF, NHLBI, AHA, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.

Landmark trials

• Wilding JPH, Batterham RL, Calanna S, et al. (STEP-1). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
• Pi-Sunyer X, Astrup A, Fujioka K, et al. (SCALE). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232.
• Perkovic V, Tuttle KR, Rossing P, et al. (FLOW). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121.

Biology of weight regulation

• Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621–628.
• Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387:1947–1956.

National programmes and resources

• Health Promotion Board Singapore. Healthy Weight resources. healthhub.sg
• Healthier SG and Chronic Tier information. healthiersg.gov.sg
• Health Sciences Authority, Singapore. New drug approvals — June 2025 (Mounjaro KwikPen: type 2 diabetes and weight management indications). hsa.gov.sg

This information is for general education only and is not a substitute for medical advice. Medical weight management is individualised — the right combination of lifestyle, medication, and (in selected patients) surgery depends on your specific metabolic picture, comorbidities, preferences, and life circumstances. Please speak with our team. v1.1 · October 2026 (v1.0 April 2026) · Review due April 2028.